Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Ubrogepant

(Ubrelvy®)

Ubrogepant

Drug updated on 4/18/2024

Dosage FormTablet (oral; 50 mg, 100 mg)
Drug ClassCalcitonin gene-related peptide receptor antagonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the acute treatment of migraine with or without aura in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ubrogepant (Ubrelvy) is indicated for the acute treatment of migraine with or without aura in adults. It offers comparable relief at doses of 50 mg and 100 mg, but the lower dose has fewer adverse events.
  • This information stems from a review of 15 studies on ubrogepant's efficacy and safety in comparison to other medications used for acute migraine treatment.
  • Compared to lasmiditan (200mg), which showed a high two-hour pain freedom but also higher incidence of dizziness, nausea, and somnolence, ubrogepant demonstrated similar efficacy rates as rimegepant but had a better tolerability profile.
  • Lasmiditan potentially offered faster onset action than both rimegepant and ubrogepant; however, this came with increased risk for mild-to-moderate self-limiting neurological adverse events.
  • Adverse drug reactions correlated with demographic/clinical characteristics such as dosage size, Body Mass Index (BMI), age, baseline aura symptoms, indicating that careful selection should be made considering these factors.
  • CGRP antagonists like ubrogepant have shown more effectiveness than placebo treatments while presenting safer alternatives to triptans, especially in patients suffering from co-existing cardiovascular diseases due to their lack of cardiovascular risks, despite being less effective in certain metrics compared to some triptans.
  • Ubrogepant, along with other CGRP antagonists, represents significant advancements in treating migraines, particularly beneficial for individuals who cannot tolerate or have contraindications against using triptans due to its favorable tolerance levels among many patients.
  • The effectiveness, coupled with its adverse drug reaction (ADR) profile, underscores the importance of a personalized medicine approach towards treating migraines, where dosages are tailored according to individual profiles to minimize side effects while maximizing relief benefits.

Product Monograph / Prescribing Information

Document TitleYearSource
Ubrelvy (ubrogepant) Prescribing Information. 2023Allergan USA Inc., Madison, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of ubrogepant for migraine: a meta-analysis of randomized controlled studies.2024International Journal of Neuroscience
Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature.2023Cephalalgia
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.2022Journal of Headache and Pain
Comparative efficacy and safety of rimegepant, ubrogepant and lasmiditan for acute treatment of migraine: a network meta-analysis.2022Expert Review of Pharmacoeconomics & Outcomes Research
Safety evaluation of oral calcitonin-gene–related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis.2022European Journal of Clinical Pharmacology
Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies.2022Expert Opinion on Drug Safety
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.2022Journal of Headache and Pain
Ditans vs Gepants: a systematic review and indirect network meta-analysis for comparative analysis of efficacy and safety.2021Neurology India
Comparative efficacy of oral calcitonin-gene–related peptide antagonists for the treatment of acute migraine: updated meta-analysis.2021Clinical Drug Investigation
Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine. 2021Medicine
Comparison of new pharmacologic agents with triptans for treatment of migraine.2021Journal of the American Medical Association
Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis.2021Journal of the American Medical Association
Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials.2020CNS Drugs
Gepants for abortive treatment of migraine: A network meta-analysis.2020Brain and Behavior
Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine.2019Frontiers in Pharmacology

Clinical Practice Guidelines

Document TitleYearSource
The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice.2021Headache